Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N et al. (2003). "Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase". Nat. Med. 9 (10): 1269?74. doi:10.1038/nm934. PMID14502282.
Jiang T, Sun Y, Yin Z, Feng S, Sun L, Li Z (2015). "Research progress of indoleamine 2,3-dioxygenase inhibitors". Future Med Chem 7 (2): 185?201. doi:10.4155/fmc.14.151. PMID25686005.
Chiarugi A, Dello Sbarba P, Paccagnini A, Donnini S, Filippi S, Moroni F (Aug 2000). "Combined inhibition of indoleamine 2,3-dioxygenase and nitric oxide synthase modulates neurotoxin release by interferon-gamma-activated macrophages". Journal of Leukocyte Biology 68 (2): 260?6. PMID10947071.
Lee H, Jeong Y, Lee T, Jung I, Lee J, Lee C et al. (May 2007). "Rosmarinic acid inhibits indoleamine 2,3-dioxygenase expression in murine dendritic cells". Biochemical Pharmacology 73 (9): 1412?21. doi:10.1016/j.bcp.2006.12.018. PMID17229401.
Cesario A, Rocca B, Rutella S (2011). "The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer". Current Medicinal Chemistry 18 (15): 2263?71. doi:10.2174/092986711795656063. PMID21517752.
Hou D, Muller A, Sharma M, DuHadaway J, Banerjee T, Johnson M et al. (2007). "Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses". Cancer Res. 67 (2): 792?801. doi:10.1158/0008-5472.CAN-06-2925. PMID17234791.
